Dietary antioxidant inhibits lipoprotein oxidation and renal injury in experimental focal segmental glomerulosclerosis

Kidney International

Volumn 51, Issue 4, 1997, Pages 1151-1159

  Lee, Hyun Soon ^a   Jeong, Jun Yong ^a   Kim, Bong Cho ^a   Kim, Young Sook ^a   Zhang, Yuan Zheng ^a   Chung, Hong Keun ^a  

^a Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; PROBUCOL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FOCAL GLOMERULOSCLEROSIS; HYPERCHOLESTEROLEMIA; KIDNEY INJURY; LIPID PEROXIDATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

EID: 0030989019     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1038/ki.1997.158     Document Type: Article

References (55)

1. MOORHEAD JF, CHAN MK, EL-NAHAS M, VARGHESE Z: Lipid nephrotoxicity in chronic progressive glomerular and tubulointerstitial disease. Lancet 2:1309-1311, 1982
2. KEANE WF, KASISKE BL, O'DONNELL MP: Lipids and progressive glomerulosclerosis. A model analogous to atherosclerosis. Am J Nephrol 8:261-271, 1988
3. DIAMOND JR, KARNOVSKY MJ: Focal and segmental glomerulosclerosis: Analogies to atherosclerosis. Kidney Int 33:917-924, 1988
4. QUINN MT, PARTHASARATHY S, FONG LG, STEINBERG, D: Oxidatively modified low density lipoproteins: A potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci USA 84:2995-2998, 1987
5. HABERLAND ME, FONG D, CHENG L: Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science 241:215-218, 1988
6. PALINSKI W, ROSENFELD ME, YLÄ-HERTTUALA S, GURTNER GC, SOCHER SS, BUTLER SW, PARTHASARATHY S, CAREW TE, STEINBERG D, WITZTUM JL: Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA 86:1372-1376, 1989
7. YLÄ-HERTTUALA S, PALINSKI W, ROSENFELD M, PARTHASARATHY S, CAREW TE, BUTLER S, WITZTUM JL, STEINBERG D: Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 84:1086-1095, 1989
8. STEINBERG D, PARTHASARATHY S, CAREW TE, KHOO JC, WITZTUM JL: Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320:915-924, 1989
9. PARTHASARATHY S, YOUNG SG, WITZTUM JL, PITTMAN RC, STEINBERG D: Probucol inhibits oxidative modification of low density lipoprotein. J Clin Invest 77:641-644, 1986
10. MARSHALL FN: Pharmacology and toxicology of probucol. Artery 10:7-21, 1982
11. KITA T, NAGANO Y, YOKODE M, ISHI K, KUME N, OOSHIMA S, YOSHIDA H, SAWAI C: Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci USA 84:5928-5931, 1987
12. CAREW TE, SCHWENKE DC, STEINBERG D: Antiatherogenic effect of probucol unrelated to its hypercholesterolemic effect: Evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci USA 84:7725-7729, 1987
13. SASAHARA M, RAINES EW, CHAIT A, CAREW TE, STEINBERG D, WAHL PW, ROSS R: Inhibition of hypercholesterolemia-induced atherosclerosis in nonhuman primate by probucol. I. Is the extent of atherosclerosis related to resistance of LDL to oxidation? J Clin Invest 94:155-164, 1994
14. LANNIGAN R, KARK R, POLLAK VE: The effect of a single intravenous injection of aminonucleoside of puromycin on the rat kidney. J Pathol Bacteriol 83:357-362, 1962
15. GLASSER RJ, VELOSA JA, MICHAEL AF: Experimental model of focal sclerosis. I. Relationship to protein excretion in aminonucleoside nephrosis. Lab Invest 36:519-526, 1977
16. DIAMOND JR, KARNOVSKY MJ: Focal and segmental glomerulosclerosis following a single intravenous dose of puromycin aminonucleoside. Am J Pathol 122:481-487, 1986
17. DIAMOND JR, BONVENTRE JV, KARNOVSKY MJ: A role for oxygen free radical in aminonucleoside nephrosis. Kidney Int 29:478-483, 1986
18. HIRANO T, MAMO JCL, NAGANO S, SUGISAKI T: The lowering effect of probucol on plasma lipoprotein and proteinuria in puromycin aminonucleoside-induced nephrotic rats. Nephron 58:95-100, 1991
19. HIRANO T, MOROHOSHI T: Treatment of hyperlipidemia with probucol suppresses the development of focal and segmental glomerulosclerosis in chronic aminonucleoside nephrosis. Nephron 60:443-447, 1992
20. TRACHTMAN H, DEL PIZZO R, FUTTERWEIT S, LEVINE D, RAO PS, VALDERRAMA E, STURMAN JA: Taurine attenuates renal disease in chronic puromycin aminonucleoside nephropathy. Am J Physiol 262: F117-F123, 1992
21. RICARDO SD, BERTRAM JF, RYAN GB: Antioxidants protect podocyte foot processes in puromycin aminonucleoside-treated rats. J Am Soc Nephrol 4:1974-1986, 1994
22. TRACHTMAN H, SCHWOB N, MAESAKA J, VALDERRAMA E: Dietary vitamin E supplementation ameliorates renal injury in chronic puromycin aminonucleoside nephropathy. J Am Soc Nephrol 5:1811-1819, 1995
23. PEDRAZA-CHAVERRI J, AREVALO AE, HERNANDEZ-PANDO R, LARRIVA-SAHD J: Effect of dietary antioxidants on puromycin aminonucleoside nephrotic syndrome. Int J Biochem Cell Biol 27:683-691, 1995
24. CHAPMAN MJ: Animal lipoproteins: Chemistry, structure and comparative aspects. J Lipid Res 21:789-853, 1980
25. JOVEN J, MASSANA L, VILLABONA C, VILELLA E, BARGALLO T, TRIAS M, FIGUERAS M, TURNER PR: Low density lipoprotein metabolism in rats with puromycin aminonucleoside-induced nephrotic syndrome. Metabolism 38:491-495, 1989
26. DIAMOND JR, KARNOVSKY MJ: Exacerbation of chronic aminonucleoside nephrosis by dietary cholesterol supplementation. Kidney Int 32:671-677, 1987
27. PESEK-DIAMOND I, DING G, FRYE J, DIAMOND JR: Macrophages mediate adverse effects of cholesterol feeding in experimental nephrosis. Am J Physiol 263:F776-F783, 1992
28. KASISKE BL, O'DONNELL MP, SCHMITZ PG, KIM Y, KEANE WF: Renal injury of diet-induced hypercholesterolemia in rats. Kidney Int 37:880-891, 1990
29. KEANE WF: Lipids and the kidney. Kidney Int 46:910-920, 1994
30. MAGIL AB, FROHLICH JJ, INNIS SM, STEINBRECHER UP: Oxidized low-density lipoprotein in experimental focal glomerulosclerosis. Kidney Int 43:1243-1250, 1993
31. SMITH PK, KROHN RI, HERMANSON GT, MALLIA AK, GARTNER FH, PROVENZANO MD, FUJIMOTO EK, GOEKE NM, OLSON BJ, KLENK DC: Measurement of protein using bicinchoninic acid. Anal Biochem 150:76-85, 1985
32. FRIEDWALD WT, LEVY RI, FREDRICKSON DS: Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 18:499-502, 1972
33. MOREL DW, CHISOLM GM: Antioxidant treatment of diabetic rats inhibits lipoprotein oxidation and cytotoxicity. J Lipid Res 30:1827-1834, 1989
34. YAGI K: A simple fluorometric assay for lipoperoxide in blood plasma. Biochem Med 15:212-216, 1976
35. LEE HS, KOH HI: Visualization of binding and uptake of oxidized low density lipoproteins by cultured mesangial cells. Lab Invest 71:200-208, 1994
36. LEE HS, KIM BC, KIM YS, CHOI KH, CHUNG HK: Involvement of oxidation in LDL-induced collagen gene regulation in mesangial cells. Kidney Int 50:1582-1590, 1996
37. DIJKSTRA CD, DOPP EA, JOLING P, KRALL G: The heterogeneity of mononuclear phagocytes in lymphoid organs: Distinct macrophage subpopulations in the rat recognized by monoclonal antibodies ED1, ED2, and ED3. Immunology 54:589-599, 1985
38. WEIBEL ER, GOMEZ DM: A principle for counting tissue structures on random sections. J Appl Physiol 17:343-348, 1962
39. LEE HS, KIM TS: A morphometric study of preeclamptic nephropathy with focal segmental glomerulosclerosis. Clin Nephrol 44:14-21, 1995
40. LEE HS, LEE JS, KOH HI, KO KW: Intraglomerular lipid deposition in routine biopsies. Clin Nephrol 36:67-75, 1991
41. HOOVER GA, MCCORMICK S, KALANT N: Interaction of native and cell-modified low density lipoprotein with collagen gel. Arteriolosclerosis 8:525-534, 1988
42. SRINIVASAN SR, VIJAYAGOPAL P, EBERLE K, RADHAKRISHNAMURTHY B, BERENSON GS: Low-density lipoprotein binding affinity of arterial wall proteoglycans: Characteristics of a chondroitin sulfate proteoglycan subfraction. Biochim Biophys Acta 1006:159-166, 1989
43. NAGASAWA HT, SWINGLE KF, ALEXANDER CS: Mechanism of aminonuceloside in the rat and guinea pig. Biochem Pharmacol 16:2211-2219, 1967
44. KEANE WF, O'DONNELL MP, KASISKE BL, KIM Y: Oxidative modification of low-density lipoproteins by mesangial cells. J Am Soc Nephrol 4:187-194, 1993
45. WHEELER DC, CHANA RS, TOPLEY N, PETERSEN MM, DAVIES M, WILLIAMS JD: Oxidation of low density lipoprotein by mesangial cells may promote glomerular injury. Kidney Int 45:1628-1636, 1994
46. BOYCE NW, TIPPING PG, HOLDSWORTH SR: Glomerular macrophages produce reactive oxygen species in experimental glomerulonephritis. Kidney Int 35:778-782, 1989
47. 2-generation, MHC class II expression, and eicosanoid synthesis. Am J Pathol 134:431-437, 1989
48. RIE J, SILBIGER S, NEUGARTEN J: Glomerular macrophages in nephrotoxic serum nephritis are activated to oxidize low-density lipoprotein. Am J Kidney Dis 26:362-367, 1995
49. JIALAL I, GRUNDY SM: Effect of dietary supplementation with alpha-tocopherol on the oxidative modification of low density lipoprotein. J Lipid Res 33:899-906, 1992
50. BARNHART JW, SEFRANKA JA, MCINTOSH PP: Hypocholesterolemic effect of probucol. Am J Clin Nutr 23:1229-1233, 1970
51. BUCKLEY MM, GOA KL, PRICE AH, BROGDEN RN: Probucol: A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolemia. Drugs 37:761-800, 1989
52. NATHAN CF: Secretory products of macrophages. J Clin Invest 79:319-326, 1987
53. VAN GOOR H, VAN DER HORST MLC, FIDLER V, GROND J: Glomerular macrophage modulation affects mesangial expansion in the rat after renal ablation. Lab Invest 66:564-571, 1992
54. DIAMOND JR, DING G, FRYE J, DIAMOND I-P: Glomerular macrophages and the mesangial proliferative response in the experimental nephrotic syndrome. Am J Pathol 141:887-894, 1992
55. BROWN MS, GOLDSTEIN JL: Scavenging for receptors. Nature 343: 508-509, 1990